Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy radiotherapy. The study demonstrated an improvement in 3-year freedom from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback